Table 1.
Association of pre- and post-NACT EV levels with clinical parameters.
| EV concentration (109/ml) |
||||
|---|---|---|---|---|
| N | pre-NACT | post-NACT | ||
| Menopausal status2 | premenopausal | 47 | 2064 (168 – 12980) | 2340 (474 – 5360) |
| perimenopausal | 16 | 2579 (550 – 6160) | 3210 (504 – 9600) | |
| postmenopausal | 42 | 2004 (263 – 7648) | 2483 (299 – 57280) | |
| Histologic finding2,3 | ductal | 77 | 2064 (263 – 12980) | 2540 (299 – 23350) |
| lobular | 14 | 2004 (168 – 5285) | 2401 (1620 – 57280) | |
| other | 13 | 2264 (1070 – 5600) | 2635 (950 – 3858) | |
| Tumor grading2,3 | G1 | 8 | 1892 (263 – 2976) | 2129 (880 – 3192) |
| G2 | 46 | 1838 (168 – 12980) | 2446 (474 – 57280) | |
| G3 | 49 | 2260 (395 – 7648) | 2815 (299 – 23350) | |
| Tumor size pre-NACT2,3 | cT1a – cT1c | 24 | 1956 (263 – 7648) | 2623 (639 – 23350) |
| cT2 | 65 | 2012 (394 – 12980) | 2352 (299 – 57280) | |
| >cT2 | 15 | 2472 (168 – 5285) | 2517 (1182 – 3858) | |
| Nodal status pre-NACT2 | cN0 | 56 | 1778 (168 – 7648)* | 2304 (504 – 23350) |
| cN1 | 42 | 2247 (394 – 6160)* | 2613 (299 – 7664) | |
| cN2, cN3 | 7 | 2590 (1044 – 12980)* | 3275 (1182 – 57280) | |
| Tumor size post-NACT2,3 | ypTis, ypT0 | 27 | 1695 (589 – 7648) | 2610 (299 – 23350) |
| ypT1a | 10 | 1738 (1023 – 4400) | 2470 (1224 – 5304) | |
| ypT1b, ypT1c | 32 | 2225 (263 – 12980) | 2529 (474 – 9600) | |
| ypT2 | 27 | 1995 (168 – 5285) | 2370 (558 – 57280) | |
| > ypT2 | 8 | 3118 (551 – 4044) | 2790 (1713 – 3858) | |
| Nodal status post-NACT2,3 | yN0 | 68 | 1780 (168 – 7648)* | 2422 (504 – 23350) |
| yN1 | 26 | 2431 (394 – 6160)* | 2668 (299 – 7664) | |
| yN2, yN3 | 10 | 2744 (551 – 12980)* | 3168 (474 – 57280) | |
| Estrogen receptor1 | pos | 74 | 2038 (168 – 12980) | 2342 (299 – 23350)* |
| neg | 31 | 2121 (395 – 7648) | 3020 (524 – 57280)* | |
| Progesterone receptor1 | pos | 66 | 1985 (168 – 12980) | 2361 (474 – 23350) |
| neg | 39 | 2220 (395 – 7648) | 2895 (299 – 57280) | |
| HER2 status1 | pos | 30 | 2169 (394 – 5600) | 2419 (561 – 9440) |
| neg | 75 | 1995 (168 – 12980) | 2520 (299 – 57280) | |
| Tumor subtype (IHC)2 | ER-, PR-, HER2- | 20 | 1797 (395 – 7648) | 2958 (524 – 57280) |
| ER-, PR-, HER2+ | 9 | 3110 (1593 – 5600) | 3360 (1236 – 4552) | |
| ER+/PR+, HER2- | 54 | 2004 (168 – 12980) | 2361 (299 – 23350) | |
| ER+, PR+, HER2+ | 22 | 2022 (394 – 4032) | 2256 (561 – 9440) | |
| NACT regimen2 | CTX | 70 | 2004 (168 – 12980) | 2612 (474 – 57280) |
| CTX + T | 17 | 2478 (1020 – 4962) | 2610 (1236 – 9440) | |
| CTX + T + L | 7 | 2216 (1044 – 4400) | 2304 (639 – 3360) | |
| CTX + A | 4 | 2140 (1092 – 3510) | 1813 (299 – 3425) | |
| HTX | 7 | 1590 (263 – 4044) | 960 (558 – 3858) | |
| Response1,3 | response | 95 | 1995 (168 – 7648)* | 2370 (299 – 57280) |
| no response | 8 | 3139 (1212 – 12980)* | 2973 (2520 – 4680) | |
| Survival (OS)1 | alive | 97 | 2012 (168 – 7648) | 2370 (299 – 57280)* |
| dead | 8 | 3207 (1160 – 12980) | 3326 (2517 – 7664)* | |
| Recurrence (3y-PFS)1,3 | alive | 83 | 1995 (168 – 12980) | 2352 (299 – 57280)** |
| relapsed | 8 | 1920 (1160 – 6160) | 3850 (2517 – 23350)** | |
EV levels pre-NACT [median (range) 109/ml] were related to the lymph node infiltration pre- and post-NACT (Kruskal-Wallis test) and to the neoadjuvant therapy response (Mann-Whitney test). Post-NACT EV levels were associated with estrogen receptor expression (Mann-Whitney test), 3y-PFS (Mann-Whitney test) and OS (Mann-Whitney test). A – Avastin, CTX – chemotherapy, ER – estrogen receptor, HER2 – human epidermal growth factor receptor-2, HTX – hormonal therapy, L – Lapatinib, neg – negative, pos – positive, PR – progesterone receptor, T – Trastuzumab.
*
p < 0.05.
**
p < 0.01.
1
Mann-Whitney test.
2
Kruskal-Wallis test.
3
not all patients are included due to missing patient data.